New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
07:01 EDTBLRXBioLineRx receives notice of allowance for U.S. patent
BioLineRx announced that a Notice of Allowance has been issued by the United States Patent and Trademark Office for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients. This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and use thereof are granted or pending in Europe, Japan, Canada, Israel, India, China, Brazil, Russia, Australia, South Africa and Hong Kong. CEO Kinneret Savitsky said, "BL-7010 for the treatment of celiac disease is one of our lead clinical programs. We are currently testing its safety and tolerability in a Phase 1/2 trial in well-controlled celiac patients. We previously announced successful completion of the single-dose escalation part of the study, and the 14-day, repeated administration part of the study is currently ongoing. We look forward to the results of this Phase 1/2 trial, expected in the next few weeks, which will enable selection of the optimal dose for future development. Following completion of this study, we plan to commence a randomized, controlled efficacy study in celiac patients."
News For BLRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
06:13 EDTBLRXBioLineRx announces Bellerophon reported results from BCM clinical trial
Subscribe for More Information
July 16, 2015
16:34 EDTBLRXBioLineRx files $75M mixed securities shelf
Subscribe for More Information
July 15, 2015
11:55 EDTBLRXBioLineRx management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use